A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said ...
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes ...
Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...
Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...
Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results